ACAAI: Novel Immunotherapy Found Safe, Effective
Promise seen for allergen-independent immunostimulatory CpG oligonucleotide G10
MONDAY, Nov. 10 (HealthDay News) -- CYT003-QbG10 -- a novel allergen-independent immunotherapeutic consisting of a virus-like particle loaded with the immunostimulatory CpG oligonucleotide G10 agent -- may be a safe and effective treatment for a broad range of allergic diseases, according to research presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting held Nov. 6 to 11 in Seattle.
In a phase II study, Audra Blaziene, M.D., of Vilnius University in Lithuania, and colleagues randomly assigned 80 patients with mild-to-moderate perennial allergic rhinoconjunctivitis caused by dust mites and/or cat dander to receive six weekly injections of either CYT003-QbG10 or placebo.
Compared to placebo, the researchers found that CYT003-QbG10 was associated with a significant reduction of daily rhinoconjunctivitis symptoms and increased allergen tolerance as measured by a conjunctival provocation test.
"This opens a new avenue for a disease-modifying and allergen-independent therapy able to address multiple allergies," the authors conclude.
